N. La-médiane-d-bajos, F. Prioux, and C. L. Moreau, augmentation du recours répété à l'IVG en France : des enjeux contraceptifs au report de l'âge à la maternité. Revue d'Epidémiologie et de Santé Publique):291?8. 2. World Health Organization. Medical Eligibility Criteria for Contraception Use, août, vol.6199, issue.4, 2013.

L. Ministère-des-affaires-sociales-et-de and . Santé, IVG : Un droit garanti par la loi. [consulté le 9 mars 2016] Disponible sur: http://www.ivg.social-sante.gouv.fr/un-droitgaranti-par-la-loi .html 5. Vilain A. Les interruptions volontaires de grossesse en 2015, Juin, issue.0968, 2016.

M. Mazuy, L. Toulemon, and E. Baril, Un recours moindre à l'IVG, mais plus souvent répété, Population & Sociétés. Janvier, vol.518, pp.1-4, 2015.

M. Mazuy, L. Toulemon, and E. Baril, Le nombre d'IVG est stable, mais moins de femmes y ont recours, Population, vol.69, issue.3, pp.365-395, 2014.
DOI : 10.3917/popu.1403.0365

URL : http://www.cairn.info/load_pdf.php?ID_ARTICLE=POPU_1403_0365

P. Dolley, G. Carles, and F. Salaun, Disponible sur: http://www.ivg.socialsante .gouv.fr/ivg-quels-sont-les-delais-a-respecter.html 9. ANAES. Prise en charge de l'interruption volontaire de grossesse jusqu'à 14 semaines. Mars, Ministère des Affaires sociales et de la Santé. Interruption volontaire de grossesse dossier guide, pp.123-168, 2001.

N. Kapp, P. Lohr, T. Ngo, J. Hayes, M. Mueller et al., Cervical preparation for first trimester surgical abortion Perioperative antibiotics to prevent infection after first-trimester abortion, CD007207. 12. Low N, pp.5217-5230, 2010.

P. Faucher and . Antibioprophylaxie, Mises À Jour En Gynécologie Médicale. 2013;249?61. 14. Contraception chez la femme après une IVG -Fiche mémo-HAS, p.2013

F. Mulet and P. Descamps, Contraception du post-partum et du post-abortum, Compterendu des 30èmes journées nationales du CNGOF, 2006.

H. Autorité and D. Santé, Contraception chez l'adolescente -Fiche Mémo, 2015.

C. Moreau, J. Desfrères, and N. Bajos, Circonstances des échecs et prescription contraceptive post-IVG : analyse des trajectoires contraceptives autour de l'IVG. 22 juin, 148?61. 18. Faucher P, Serfaty D. La contraception après une interruption volontaire de grossesse, 2011.

U. Médecine-thérapeutique-médecine-reprod-gynécologie-endocrinol-upadhyay, B. Brown, A. Sokoloff, and T. Raine, Contraceptive discontinuation and repeat unintended pregnancy within 1 year after an abortion):56?62. 20. Bayer HealthCare. Jaydess®-What is Jaydess®? : Brochure d'information aux patients [consulté le 15 mars 2015, Disponible sur, 2012.

K. Gemzell-danielsson, B. Hauck, K. Rosen, and C. Zurth, Disponible sur: http://agence-prd.ansm.sante.fr/php Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies, Résumé des Caractéristiques du Produit : Jaydess. [consulté le 15 mars 2016, pp.1656-1662, 2014.

D. Serfaty, Les dispositifs intra-utérins. 24ème Journée Nationale-Collège National des Gynécologues Obstétriciens Fr, 2000.
DOI : 10.1016/b978-2-294-70921-0.00007-3

I. Järvelä, A. Tekay, P. D. Jouppila, B. Hauck, T. Schmelter et al., The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women Disponible sur: https://www.vidal.fr/Medicament/jaydess-133035-pharmacodynamie.htm 26 Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial, Hum Reprod Oxf Engl. déc Obstet Gynecol. déc, vol.13122, issue.126, pp.1205-1218, 1998.

H. Autorité and D. Santé, Commision de la Transparence : Jaydess 13,5mg système de diffusion intra-utérin. Novembre, Disponible sur, 2013.

H. Autorité-de-santé, D. Grimes, L. Lopez, and K. Schulz, Méthodes contraceptives. Mars Disponible sur: http://www.has-sante.fr/portail/upload/docs/application/pdf/2013- 03/synthese_methodes_contraceptives_format2clics.pdf 29 Antibiotic prophylaxis for intrauterine contraceptive device insertion, Cochrane Database of Systematic Reviews [Internet], 2013.

J. Wiley, &. Sons, L. Heinemann, K. Reed, S. Moehner et al., Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices Use of the levonorgestrel-releasing intrauterine system in breast cancer patients):17?22. 32. Bayer HealthCare. Comparison of Jaydess & Mirena Information for Health Care professionale Disponible sur: http://www.jaydess.com/comparison-jaydess-mirena 33. Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena Ovarian cysts: presence and persistence with use of a 13.5mg levonorgestrel-releasing intrauterine system randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena, Disponible sur274?9. 31, pp.616-622, 1999.

D. Apter, A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents. Contraception, 2016.

I. Cristobal, J. Neyro, and I. Lete, The new LNG-releasing IUS: a new opportunity to reduce the burden of unintended pregnancy, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.190, pp.58-64, 2015.
DOI : 10.1016/j.ejogrb.2015.04.016

S. Goodman, S. Hendlish, M. Reeves, A. Foster-rosales, D. Grimes et al., Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion Immediate postabortal insertion of intrauterine devices):CD001777. 41. American College of Obstetricians and Gynecologists Intrauterine device and adolescents):1493?5. 42. Medical Eligibility Criteria for Contraceptive UseDisponible sur, Contraception. août Cochrane Database Syst Rev. ACOG Committee Opinion No. Obstet Gynecol. déc Geneva: World Health, vol.78110, issue.3926, pp.143-151, 2007.

C. Moreau, A. Bohet, D. Hassoun, M. Teboul, N. Bajos et al., Trends and determinants of use of long-acting reversible contraception use among young women in France: results from three national surveys conducted between Board of the Society of Family Planning. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women Intrauterine contraception for Nulliparous women: Translating Research into Action (INTRA) group. A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women Contraceptive policies affect post-abortion provision of long-acting reversible contraception, 451?8. 44. Lyus R, pp.367-71, 2000.

C. Moreau, A. Bohet, D. Hassoun, V. Ringa, S. Bajos-n-alehagen et al., IUD use in France: women's and physician's perspectives Likelihood of repeat abortion in a Swedish cohort according to the choice of post-abortion contraception: a longitudinal study Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion Estimates of contraceptive failure from the 2002 National Survey of Family Growth, 565?71. 49. Steinauer JE, pp.10-21, 2008.

N. Bajos, A. Bohet, L. Guen, M. Moreau, C. Landry et al., La contraception en France : nouveau contexte, nouvelles pratiques ? Population & Sociétés Public and private providers' involvement in improving their patients' contraceptive use, sept Contraception. juill, vol.78, issue.4921, pp.1-4, 2008.

N. Stanwood, K. Bradley, S. Bennia-bouraï, I. Asselin, and M. Vallée, Young pregnant women's knowledge of modern intrauterine devices Contraception et adolescence Une enquête un jour donné auprès de 232 lycéens (Caen) Médecine. 1 févr Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices IUDs and adolescents--an under-utilized opportunity for pregnancy prevention, Obstet Gynecol. déc Obstet Gynecol. oct J Pediatr Adolesc Gynecol. juin, vol.108212023, issue.56243, pp.84-93, 2006.

M. Rosenberg and M. Waugh, Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons, American Journal of Obstetrics and Gynecology, vol.179, issue.3, pp.577-82, 1998.
DOI : 10.1016/S0002-9378(98)70047-X

P. Rivière, L. Borgatta, K. Buhling, S. Rybowski, K. Roth et al., Thèse : Médecine : Versailles Saint-Quentin-en-Yvelines A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age Preventing Unintended Pregnancy: The Contraceptive CHOICE Project in Review Immediate postabortal insertion of intrauterine devices, Freins et réticences à l'utilisation du dispositif intra-utérin chez les nulipares en médecine générale : étude quantitative. 111p372?9. 62. Birgisson NECD001777. 64. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception, pp.61121-61158, 2002.

O. Heikinheimo, P. Inki, M. Kunz, S. Parmhed, A. Anttila et al., Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system, Contraception, vol.81, issue.6, pp.481-487, 2010.
DOI : 10.1016/j.contraception.2010.01.020

D. Costescu, Levonorgestrel-releasing intrauterine systems for long-acting contraception: current perspectives, safety, and patient counseling, International Journal of Women's Health, vol.8, pp.589-98, 2016.
DOI : 10.2147/IJWH.S99705

URL : http://doi.org/10.2147/ijwh.s99705

M. Guyomar and G. Guilloteau, Que pensent les gynécologues et les médecins généralistes posant des dispositifs intra-utérins de ce mode de contraception chez la femme nullipare .37p, Thèse : Médecine : Angers, p.2012

E. Bizzotto, Contraception : augmentation exponentielle des ventes de stérilet, 2013.